Clinical trials: Advanced Gastrointestinal Tumors
Colon Cancer, Colorectal Cancer
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
The purpose of this research study is to evaluate the safety and effectiveness of pegfilgrastim in reducing grade 3/4 neutropenia when given after one of three chemotherapy regimens (FOIL, FOLFOX or FOLFIRI) in patients with…
- Conditions
- Colon Cancer, Colorectal Cancer, Rectal Cancer
- Trial name
- NCT00094809
- Testing
- Pegfilgrastim
- Volunteers
- 252 people
- Sponsor
- Amgen
Solid Tumors, Gastric Cancer
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study.
- Conditions
- Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
- Trial name
- NCT06710132
- Testing
- M9140
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 184 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Biliary Tract Cancer, Gallbladder Cancer
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free survival (PFS) at the trial closure in…
- Conditions
- Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma
- Trial name
- VANGOGH (NCT00753675)
- Testing
- ZD6474, Vandetanib, Gemcitabine
- Where
- 15 sites in Italy
- Volunteers
- 174 people
- Sponsor
- Genzyme, a Sanofi Company
Carcinoma, Hepatocellular
A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer
This study will evaluate the efficacy and safety of capecitabine (Xeloda) in combination with peginterferon alfa-2a (Pegasys) in participants with advanced liver cancer who have had no prior treatment.
- Trial name
- NCT02576964
- Testing
- Capecitabine, Peginterferon alfa-2a
- Where
- 8 sites in China, Taiwan and 1 more
- Volunteers
- 16 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma
The study is an exploratory clinical trial initiated by an open, single arm researcher to evaluate the safety, tolerability, and preliminary efficacy of BST06 injection in the treatment of advanced hepatocellular carcinoma in…
- Trial name
- NCT06645314
- Testing
- Group A, Group B
- Volunteers
- 16 people
- Sponsor
- BioSyngen Pte Ltd
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Gastric Cancer, Gastroesophageal Junction Cancer
A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
The purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
- Trial name
- GAMBIT (NCT07143604)
- Testing
- AZD0901
- Where
- 13 sites in Russia
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
HER2 Positive Gastric Cancer, Colorectal Cancer
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: Regimen A: FATE-NK100 as a monotherapy in subjects with advanced…
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor
- Trial name
- NCT03319459
- Testing
- FATE-NK100, Cetuximab, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Fate Therapeutics
Colorectal Cancer, Gastric Cancer
Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer
This is an open-label, multi-center, dose escalation study in adult subjects with advanced colorectal, gastric, hepatic or pancreatic cancer.
- Conditions
- Colorectal Cancer, Gastric Cancer, Hepatic Cancer, Pancreatic Cancer
- Trial name
- NCT02191761
- Testing
- SM04755
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Biosplice Therapeutics, Inc.
Gastric Cancer, GastroEsophageal Cancer
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and…
- Trial name
- NCT04099641
- Testing
- Bavituximab, Pembrolizumab Injection
- Where
- 21 sites in United States, South Korea and 2 more
- Volunteers
- 80 people
- Sponsor
- OncXerna Theraputics, Inc.
Advanced Solid Tumors, Gastric Cancer
Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer, Pancreatic Cancer
- Trial name
- NCT05275062
- Testing
- IM92 CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Gastric Cancer, Gastroesophageal Junction Cancer
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and…
- Trial name
- BRIGHTER (NCT02178956)
- Testing
- BBI608, Paclitaxel
- Where
- 263 sites in United States, Australia and 20 more
- Volunteers
- 714 people
- Sponsor
- Sumitomo Pharma America, Inc.
Colorectal Neoplasm
Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
This trial is being performed in two parts: Dose Escalation and Dose Expansion. The primary objective for the Dose Escalation part is to determine the safety and tolerability at different doses of DS-8273a administered in…
- Trial name
- NCT02991196
- Testing
- DS-8273a + nivolumab
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Daiichi Sankyo
Hepatocellular Carcinoma
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in…
- Trial name
- NCT06558227
- Testing
- ZG005 for Injection, Bevacizumab, Sintilimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Pancreatic Neoplasms
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
Primary Objective: To demonstrate that the addition of oxaliplatin to 5-Fluorouracil (5-FU) and Leucovorin (LV) will improve the Progression-Free Survival (PFS).
- Trial name
- NCT01121848
- Testing
- Leucovorin, OXALIPLATIN, 5-Fluorouracil
- Where
- 15 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Sanofi
Advanced Solid Tumor, Hepatocellular Carcinoma
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.
- Trial name
- NCT06005740
- Testing
- TORL-4-500
- Where
- 10 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
Advanced Digestive System Tumor
A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors
This is an open-label, multi-center, dose-escalation clinical study to evaluate the safety, feasibility, and preliminary efficacy of IMC002 in patients with CLDN18.2 positive digestive system tumors including but not limited to…
- Trial name
- NCT05946226
- Testing
- IMC002 injection
- Where
- 7 sites in China
- Volunteers
- 18 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Hepatocellular Carcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous…
- Trial name
- COSMIC-312 (NCT03755791)
- Testing
- Cabozantinib, Sorafenib, Atezolizumab
- Where
- 245 sites in United States, Argentina and 32 more
- Volunteers
- 837 people
- Sponsor
- Exelixis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.